{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:36:51Z","timestamp":1773815811750,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1116","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Various options for the pharmacological treatment of breakthrough cancer pain (BTcP) are available. International guidelines on BTcP treatment are not univocal. A tailored treatment should be based on the assessment of different variables such as BTcP characteristics, oral mucositis, chronic rhinitis and a patient\u2019s ability to take medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The goal of this study is to assess the relationship between these variables and the medication treatment for BTcP in a sample of patients with terminal cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective, cross-sectional study was carried out among 1180 patients who were receiving palliative care programmes. Patients were recruited if they had a diagnosis of BTcP and had been prescribed rescue opioids. Variables that might influence the BTcP treatment were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and forty-nine eligible patients were enrolled; 59.1% of patients received short-acting oral morphine (OM), 27.5% transmucosal immediate-release fentanyl (TIRF) and 13.4% parenteral morphine for BTcP treatment. Short-acting OM prescription was related to background pain treatment with OM &amp;lt;60 \u2009mg daily (p&amp;lt;0.0001) and to home-care setting of assistance (p=0.004). Continuous intravenous morphine infusion and the presence of a vascular access were the main factors related to intravenous morphine prescription for BTcP. TIRF use was mainly related to background opioid dosage and the patient\u2019s self-sufficiency in taking medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In clinical practice, the factors that most influenced the pharmacological treatment for BTcP were baseline opioid dosage, setting of assistance and self-ability to take medication. Further research is needed to improve the knowledge on tailored BTcP treatment.<\/jats:p><\/jats:sec>","DOI":"10.1136\/postgradmedj-2018-135659","type":"journal-article","created":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T16:15:12Z","timestamp":1539447312000},"page":"566-570","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer"],"prefix":"10.1093","volume":"94","author":[{"given":"Caterina","family":"Magnani","sequence":"first","affiliation":[{"name":"Research Department, Palliative Care Unit, Antea Associazione , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Istituto Regina Elena , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Calvieri","sequence":"additional","affiliation":[{"name":"Hospice Care Department, Antea , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Dardeli","sequence":"additional","affiliation":[{"name":"Hospice Care Department, Antea , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Eusepi","sequence":"additional","affiliation":[{"name":"Hospice Care Department, Antea , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosa","family":"Restuccia","sequence":"additional","affiliation":[{"name":"Hospice Care Department, Antea , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Mastroianni","sequence":"additional","affiliation":[{"name":"Educational Department, Palliative Care Unit, Antea Associazione , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Casale","sequence":"additional","affiliation":[{"name":"Health and Scientific Management, Palliative Care Unit, Antea Associazione , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,13]]},"reference":[{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejpain.2008.06.014","article-title":"The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the association for palliative medicine of great Britain and Ireland","volume":"13","author":"Davies","year":"2009","journal-title":"Eur J Pain"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1097\/j.pain.0000000000000721","article-title":"Breakthrough cancer pain: twenty-five years of study","volume":"157","author":"Mercadante","year":"2016","journal-title":"Pain"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpainsymman.2013.02.015","article-title":"Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature","volume":"47","author":"Deandrea","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","article-title":"Breakthrough pain: definition, prevalence and characteristics","volume":"41","author":"Portenoy","year":"1990","journal-title":"Pain"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jval.2016.03.002","article-title":"Breakthrough cancer pain: ten commandments","volume":"19","author":"Mercadante","year":"2016","journal-title":"Value Health"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"key":"2023041307532631300_","volume-title":"Palliative care for adults: strong opioids for pain relief","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/sj.bjc.6603811","article-title":"Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain","volume":"96","author":"Mercadante","year":"2007","journal-title":"Br J Cancer"},{"key":"2023041307532631300_","first-page":"1123","article-title":"Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article","volume":"80","author":"Corli","year":"2014","journal-title":"Minerva Anestesiol"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/JPR.S40745","article-title":"Considerations in selecting rapid-onset opioids for the management of breakthrough pain","volume":"6","author":"Smith","year":"2013","journal-title":"J Pain Res"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jpainsymman.2012.09.009","article-title":"Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials","volume":"46","author":"Jandhyala","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.suponc.2011.07.004","article-title":"Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study","volume":"9","author":"Fallon","year":"2011","journal-title":"J Support Oncol"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12325-016-0440-4","article-title":"Breakthrough cancer pain: preliminary data of the italian oncologic pain multisetting multicentric survey (IOPS-MS)","volume":"34","author":"Mercadante","year":"2017","journal-title":"Adv Ther"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jpainsymman.2012.12.009","article-title":"Breakthrough cancer pain: an observational study of 1000 European oncology patients","volume":"46","author":"Davies","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/JPR.S22641","article-title":"Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis","volume":"4","author":"Finn","year":"2011","journal-title":"J Pain Res"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/00044011-200727090-00002","article-title":"Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study","volume":"27","author":"Darwish","year":"2007","journal-title":"Clin Drug Investig"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5414\/CP201825","article-title":"Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl","volume":"51","author":"Perelman","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1191\/0269216303pm755oa","article-title":"The acceptability of different routes of administration of analgesia for breakthrough pain","volume":"17","author":"Walker","year":"2003","journal-title":"Palliat Med"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1477-7525-8-42","article-title":"Comparison of numerical and verbal rating scales to measure pain exacerbations in patients with chronic cancer pain","volume":"8","author":"Brunelli","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00520-009-0771-7","article-title":"Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life","volume":"18","author":"Cheng","year":"2010","journal-title":"Support Care Cancer"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-907673-46-7_6","volume-title":"A comparison and assessment of scoring scales for mucositis. In: oral mucositis","author":"Sonis","year":"2012"},{"issue":"9 Suppl","key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cncr.20162","article-title":"Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients","volume":"100","author":"Sonis","year":"2004","journal-title":"Cancer"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmjspcare-2015-000887","article-title":"Characteristics of breakthrough cancer pain and its influence on quality of life in an international cohort of patients with cancer","volume":"6","author":"Hjermstad","year":"2016","journal-title":"BMJ Support Palliat Care"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/AJP.0000000000000161","article-title":"Italian oncological pain survey (iops): a multicentre italian study of breakthrough pain performed in different settings","volume":"31","author":"Mercadante","year":"2015","journal-title":"Clin J Pain"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/AJP.0000000000000450","article-title":"Procedural pain in palliative care: is it breakthrough pain? a multicenter national prospective study to assess prevalence, intensity, and treatment of procedure-related pain in patients with advanced disease","volume":"33","author":"Magnani","year":"2017","journal-title":"Clin J Pain"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jpainsymman.2015.12.329","article-title":"From \u201cbreakthrough\u201d to \u201cepisodic\u201d cancer paom \u201cBreakthrough\u201d to \u201cEpisodic\u201d Cancer Pain? A European association for palliative care research network expert delphi survey toward a common terminology and classification of transient cancer pain exacern Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations","volume":"51","author":"L\u00f8hre","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00520-015-2720-y","article-title":"Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients","volume":"23","author":"Mercadante","year":"2015","journal-title":"Support Care Cancer"},{"key":"2023041307532631300_","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1185\/03007995.2012.683112","article-title":"Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses","volume":"28","author":"Mercadante","year":"2012","journal-title":"Curr Med Res Opin"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/94\/1116\/566\/49838932\/postgradmedj-94-566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/94\/1116\/566\/49838932\/postgradmedj-94-566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:41:15Z","timestamp":1693957275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/94\/1116\/566\/6959117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":28,"journal-issue":{"issue":"1116","published-online":{"date-parts":[[2018,10,13]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2018-135659","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,10,1]]}}}